Research graph
References from Letter: Reactivation Risk Estimates in <scp>HBsAg</scp> ‐Negative Patients—Definitional, Serological, and Reporting Considerations. Authors' Reply. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1111/apt.70992
10.1111/apt.70992 · External reference
Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 Update
10.1111/hepr.13504 · 2020 · External reference
Tenofovir Alafenamide for Prevention of HBV Reactivation in HBsAg‐Negative, Anti–HBc‐Positive Patients Undergoing Rituximab‐Based Chemotherapy: A Multicenter Randomized Controlled Trial
10.1097/hc9.0000000000000859 · 2025 · External reference
Incidence of Hepatitis B Virus Reactivation in Patients Treated With Immunosuppressive and Chemotherapeutic Agents
10.1111/apt.70749 · 2026 · External reference
